Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz
Efavirenz is a potent antiretroviral agent used in combination with other antiretroviral agents as part of highly active antiretroviral therapy. Efavirenz is generally well tolerated because the majority of its adverse effects are self-limiting, with central nervous symptoms and rash being the most...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2001-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/2001/645147 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551134561042432 |
|---|---|
| author | M John Gill Anita Rachlis Sharon Walmsley Mark Halman The Efavirenz Consensus Working Group |
| author_facet | M John Gill Anita Rachlis Sharon Walmsley Mark Halman The Efavirenz Consensus Working Group |
| author_sort | M John Gill |
| collection | DOAJ |
| description | Efavirenz is a potent antiretroviral agent used in combination with other antiretroviral agents as part of highly active
antiretroviral therapy. Efavirenz is generally well tolerated because the majority of its adverse effects are self-limiting,
with central nervous symptoms and rash being the most frequent. In routine practice, the discontinuation rate
of efavirenz due to adverse effects appears higher than that described in clinical trials. To minimize early treatment
interruption and maximize the benefit of long term viral suppression that can be achieved with efavirenz therapy,
health care providers and patients have identified that there is a need for information, education about and practical
tools for the management of efavirenz-related side effects. To this end, a panel of experts in the care of HIV
patients consisting of primary care physicians, infectious disease specialists, psychiatrists and pharmacists was convened.
Through the evaluation of current literature and discussion among the group, the panel arrived at consensus
recommendations. The present report outlines general management recommendations that apply to adverse effects
related to efavirenz initiation, as well as specific management strategies for central nervous system symptoms such
as agitation, sleep disturbances, dreams, dizziness, impaired concentration and depression. It is hoped that these
practical recommendations will aid clinicians in minimizing and improving patient tolerance of side effects, thereby
achieving improved adherence and patient outcomes. |
| format | Article |
| id | doaj-art-a8912907f02d4497bc2b456a070e2a09 |
| institution | Kabale University |
| issn | 1180-2332 |
| language | English |
| publishDate | 2001-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases |
| spelling | doaj-art-a8912907f02d4497bc2b456a070e2a092025-02-03T06:04:54ZengWileyCanadian Journal of Infectious Diseases1180-23322001-01-0112Suppl C20C30C10.1155/2001/645147Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to EfavirenzM John Gill0Anita Rachlis1Sharon Walmsley2Mark Halman3The Efavirenz Consensus Working GroupSouthern Alberta Clinic and Department of Medicine, University of Calgary, Calgary, Alberta, CanadaDivision of Infectious Diseases, , Department of Medicine, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, CanadaDepartment of Medicine, University of Toronto, Canada4HIV Psychiatry Program and Medical Psychiatry Consultation Service, St Michael’s Hospital, Department of Psychiatry, University of Toronto, Toronto, Ontario, CanadaEfavirenz is a potent antiretroviral agent used in combination with other antiretroviral agents as part of highly active antiretroviral therapy. Efavirenz is generally well tolerated because the majority of its adverse effects are self-limiting, with central nervous symptoms and rash being the most frequent. In routine practice, the discontinuation rate of efavirenz due to adverse effects appears higher than that described in clinical trials. To minimize early treatment interruption and maximize the benefit of long term viral suppression that can be achieved with efavirenz therapy, health care providers and patients have identified that there is a need for information, education about and practical tools for the management of efavirenz-related side effects. To this end, a panel of experts in the care of HIV patients consisting of primary care physicians, infectious disease specialists, psychiatrists and pharmacists was convened. Through the evaluation of current literature and discussion among the group, the panel arrived at consensus recommendations. The present report outlines general management recommendations that apply to adverse effects related to efavirenz initiation, as well as specific management strategies for central nervous system symptoms such as agitation, sleep disturbances, dreams, dizziness, impaired concentration and depression. It is hoped that these practical recommendations will aid clinicians in minimizing and improving patient tolerance of side effects, thereby achieving improved adherence and patient outcomes.http://dx.doi.org/10.1155/2001/645147 |
| spellingShingle | M John Gill Anita Rachlis Sharon Walmsley Mark Halman The Efavirenz Consensus Working Group Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz Canadian Journal of Infectious Diseases |
| title | Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz |
| title_full | Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz |
| title_fullStr | Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz |
| title_full_unstemmed | Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz |
| title_short | Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz |
| title_sort | canadian expert panel recommendations on the management of cns symptoms related to efavirenz |
| url | http://dx.doi.org/10.1155/2001/645147 |
| work_keys_str_mv | AT mjohngill canadianexpertpanelrecommendationsonthemanagementofcnssymptomsrelatedtoefavirenz AT anitarachlis canadianexpertpanelrecommendationsonthemanagementofcnssymptomsrelatedtoefavirenz AT sharonwalmsley canadianexpertpanelrecommendationsonthemanagementofcnssymptomsrelatedtoefavirenz AT markhalman canadianexpertpanelrecommendationsonthemanagementofcnssymptomsrelatedtoefavirenz AT theefavirenzconsensusworkinggroup canadianexpertpanelrecommendationsonthemanagementofcnssymptomsrelatedtoefavirenz |